Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects

BACKGROUND: KM-023 is a new second-generation nonnucleoside reverse-transcriptase inhibitor that is under development for the treatment of human immunodeficiency virus (HIV) type 1 infection. OBJECTIVE: This study determined KM-023 tolerability and pharmacokinetic characteristics in healthy subjects...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Yu-Jung, Lim, Kyoung Soo, Park, Min-Kyu, Schneider, Stephen, Bray, Brian, Kang, Myung-Chol, Chung, Jae-Yong, Yoon, Seo Hyun, Cho, Joo-Youn, Yu, Kyung-Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189701/
https://www.ncbi.nlm.nih.gov/pubmed/25302016
http://dx.doi.org/10.2147/DDDT.S65596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189701/
https://www.ncbi.nlm.nih.gov/pubmed/25302016
http://dx.doi.org/10.2147/DDDT.S65596

Ejemplares similares